|Analysis of BIM (BCL-2 like 11 gene) deletion polymorphism in Chinese non-small cell lung cancer patients|
|Zhong, Jia; Li, Zheng-Xiang; Zhao, Jun; Duan, Jian-Chun; Bai, Hua; An, Tong-Tong; Yang, Xiao-Dan; Wang, Jie|
|关键词||Chemotherapy Egfr Tyrosine Kinase Inhibitor Non-small Cell Lung Cancer Polymorphism|
|WOS标题词||Science & Technology|
|类目[WOS]||Oncology ; Respiratory System|
|研究领域[WOS]||Oncology ; Respiratory System|
|关键词[WOS]||GROWTH-FACTOR RECEPTOR ; INDUCED APOPTOSIS ; REGULATES BIM ; CHEMOTHERAPY ; MUTATIONS ; GEFITINIB ; EGFR ; IDENTIFICATION ; PACLITAXEL ; ERLOTINIB|
BackgroundDrug resistance significantly weakens the efficacy of cancer treatment, and the BIM (also known as the BCL2L11 gene) deletion polymorphism has been identified as a potential biomarker for drug resistance. In this retrospective study, we included a total of 290 patients with advanced non-small cell lung cancer (NSCLC) who received treatment with epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) and chemotherapy.
MethodsThe BIM deletion polymorphism of each patient was detected by polymerase chain reaction. EGFR mutations were detected by denaturing high-performance liquid chromatography methods and the amplification refractory mutation system.
ResultsThe BIM deletion polymorphism was detected in 45/290 (15.5%) Chinese NSCLC patients. No associations were observed between the BIM deletion and clinic-pathologic characteristics of patients. The BIM deletion polymorphism was predictive of shorter progression-free survival in Chinese patients with EGFR-mutant adenocarcinoma and who were treated with EGFR-TKIs (7.30 vs. 9.53 months, P = 0.034). Additionally, we found that the BIM deletion polymorphism was an effective predictor of short progression-free survival in individuals with EGFR-mutant NSCLC and treated with chemotherapy containing pemetrexed (3.32 vs. 5.30, P = 0.012) or second-/beyond-line chemotherapy containing taxanes (1.53 vs. 2.61 months, P = 0.025). The BIM deletion was not correlated with overall survival.
ConclusionThe BIM deletion polymorphism occurs in 15.5% of Chinese NSCLC patients, and is a biomarker for resistance to TKIs and chemotherapy. However, BIM deletion was not a decisive factor in overall survival.
|作者单位||Peking Univ, Dept Thorac Med Oncol, Canc Hosp & Inst, Beijing 100036, Peoples R China|
|Zhong, Jia,Li, Zheng-Xiang,Zhao, Jun,et al. Analysis of BIM (BCL-2 like 11 gene) deletion polymorphism in Chinese non-small cell lung cancer patients[J]. THORACIC CANCER,2014,5(6):509-516.|
|APA||Zhong, Jia.,Li, Zheng-Xiang.,Zhao, Jun.,Duan, Jian-Chun.,Bai, Hua.,...&Wang, Jie.(2014).Analysis of BIM (BCL-2 like 11 gene) deletion polymorphism in Chinese non-small cell lung cancer patients.THORACIC CANCER,5(6),509-516.|
|MLA||Zhong, Jia,et al."Analysis of BIM (BCL-2 like 11 gene) deletion polymorphism in Chinese non-small cell lung cancer patients".THORACIC CANCER 5.6(2014):509-516.|